Hari Reddy, DO
Allergy & Immunology · Allen, TXNPI 1235199621
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,500 of the $30,802 with a category attached, or 60.1%. Genentech USA, Inc. accounts for 66.2% of it on its own, with 26 other manufacturers making up the rest.
Across 379 payments — averaging $81.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$20K
- Sanofi$3K
- AstraZeneca$2K
- Regeneron Healthcare Solutions, Inc.$2K
- GSK$439
- Novartis$366
- plus $2K from 21 others
Across 3 payments — averaging $934.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3K
What the payments were for
- Consulting fees$1,7196%
- Speaking & faculty fees$18,50060%
- Travel & lodging$1,2194%
- Food & beverage$9,35630%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 50 | $20,401 |
| Sanofi | 44 | $3,491 |
| AstraZeneca | 78 | $2,384 |
| Regeneron Healthcare Solutions, Inc. | 73 | $1,765 |
| GSK | 38 | $439 |
| Novartis | 17 | $366 |
| AbbVie | 20 | $351 |
| ARS Pharmaceuticals Operations, Inc. | 8 | $208 |
| Grifols USA, LLC | 1 | $156 |
| Amgen | 7 | $146 |
| Optinose US, Inc. | 6 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $129 |
| Blueprint Medicines Corporation | 1 | $122 |
| Pfizer | 5 | $109 |
| CSL Behring | 1 | $106 |
| Octapharma USA, Inc. | 2 | $87 |
| Teva Pharmaceuticals USA, Inc. | 3 | $77 |
| Kaleo, Inc. | 4 | $62 |
| Lilly USA, LLC | 3 | $62 |
| Hikma Pharmaceuticals USA | 2 | $41 |
| Organon | 4 | $39 |
| Merck | 2 | $32 |
| Shire North American Group Inc | 1 | $23 |
| Incyte Corporation | 1 | $20 |
| Novo Nordisk | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $16 |
| Exact Sciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,802 in reported general payments places this provider in the 85th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $7,905 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,705 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 11 | $1,020 |
| Ipratropium Bromide | 25 | $853 |
| Montelukast Sodium | 54 | $704 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $512 |
| Azelastine Hcl | 13 | $320 |
| Fluticasone Propionate | 27 | $168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $439 | $7,90513 claims |
| AstraZenecaSymbicort | $2,384 | $3,70511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Allen
- Joseph DiazSan Antonio$1.1M
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
- Lara GrossDallas$171K
- Bobby LanierBenbrook$149K
- Juan ZambranoHouston$146K
- Serge de GolovineBellaire$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.